| Japanese |
|---|
| Title | ミトコンドリア筋症におけるヨード脂肪酸心筋シンチグラフィの臨床的検討 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 木原浩一*, 中條政敬**, 生野博久*, 阿南隆一郎*, 尾辻豊*, 中尾正一郎*, 中別府良昭**, 中川正法***, 栗山勝***, 福永秀敏****, 納光弘***, 田中弘允* |
|---|
| Authors(kana) | |
|---|
| Organization | *鹿児島大学医学部第一内科, **放射線科, ***第三内科, ****国立療養所南九州病院 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 453-461 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」心筋脂肪酸代謝を評価する目的で開発された放射性医薬品であるβ-methyl-p-(123I)iodophenylpentadecanoic acid(123I-BMIPP)を用いて, ミトコンドリア筋症における心筋障害を評価した. ミトコンドリア筋症のうち慢性進行性外眼筋麻痺(CPEO)の4例では, 123I-BMIPPの心筋への集積度は201Tlよりも高値であった. これに対し, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes(MELAS)の2例およびMyoclonus epilepsy with ragged-red fibers(MERRF)の1例では123I-BMIPPの集積度は201Tlより低値を示し, 視覚的にも両核種の所見の間に乖離が認められた. MELASおよびMERRFの3例では心エコーおよび心電図で心筋の異常所見が認められたが. CPEOの4例では特に明らかな心筋障害を示唆する所見は認められなかった. 123I-BMIPPは, 心筋ミトコンドリア機能を反映する可能性のある放射性医薬品であり, ミトコンドリア筋症における心筋障害の診断に有用と考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), Mitochondrial myopathy, Myocardial fatty acid metabolism. |
|---|
| English |
|---|
| Title | Clinical Study on Myocardial Imaging with β-Methyl-p-(123I)-Iodophenyl-Pentadecanoic Acid in Patients With Mitochondrial Myopathy |
|---|
| Subtitle | Original Article |
|---|
| Authors | Koichi KIHARA*, Masayuki NAKAJO**, Hirohisa SHONO*, Ryuichiro ANAN*, Yutaka OTSUJI*, Shoichiro NAKAO*, Yoshiaki NAKABEPPU**, Masanori NAKAGAWA***, Masaru KURIYAMA***, Hidetoshi FUKUNAGA****, Mitsuhiro OSAME***, Hiromitsu TANAKA* |
|---|
| Authors(kana) | |
|---|
| Organization | *First Department of Internal Medicine, **Department of Radiology, ***Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University, ****Department of Neurology, Minami Kyushu Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 453-461 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Myocardial imaging with β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), a new radiopharmaceutical designed to evaluate myocardial fatty acid metabolism, was performed in 7 patients with mitochondrial myopathy to detect their myocardial damages in comparison with 201Tl myocardial imaging. These patients were divided into 4 chronic progressive external ophthalmoplegia (CPEO) cases, 2 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) cases and 1 myoclonus epilepsy with ragged-red fibers (MERRF). In visual assessment, we observed more myocardial segments with decreased uptake of 123I-BMIPP compared to 201Tl in MELAS cases than in CPEO cases. The mean myocardial uptake of 123I-BMIPP was higher than that of 201Tl in CPEO cases. On the other hand, in MELAS and MERRF cases, the mean myocardial uptake of 123I-BMIPP was lower than that of 201Tl. Abnormal findings suggesting myocardial damages were observed in echocardiogram and/or in electrocardiogram in MELAS and MERRF cases, while no such abnormal findings were observed in CPEO cases. Along with the previously reported experimental result that the impairment of rat myocardial mitochondria decreased myocardial uptake of 125I-BMIPP, these results suggest that 123I-BMIPP may be useful to detect myocardial damages in patients with mitochondrial myopathy. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), Mitochondrial myopathy, Myocardial fatty acid metabolism. |
|---|